Literature DB >> 27034883

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Accompanied by Dysuria.

Hisashi Takeuchi1, Isao Kuroda1, Issei Takizawa1, Teiichiro Aoyagi1, Masaaki Tachibana2.   

Abstract

A 65-year-old male visited us with complaints of retarded urination, dysuria, gross hematuria, and fever. Urinalysis showed pyuria. Prostatic tumor with lung metastasis was suspected from computed tomography and magnetic resonance imaging. Transurethral prostatic biopsy and bronchoscopic biopsy only revealed fibrinoid necrosis and inflammatory infiltration. Right lateral maxillary sinusitis was also found by MRI. ANCA testing was positive with specificity for anti-PR3 (PR3-ANCA). On the basis of these results, Granulomatosis with polyangiitis (GPA) was diagnosed. GPA involving the prostate gland is unusual, and only a few cases have previously been reported.

Entities:  

Year:  2016        PMID: 27034883      PMCID: PMC4808535          DOI: 10.1155/2016/7812875

Source DB:  PubMed          Journal:  Case Rep Urol


1. Introduction

Granulomatosis with polyangiitis (GPA) is a form of systemic vasculitis with necrotizing granulomatous inflammation of the upper and lower respiratory tracts and kidneys [1]. On the other hand, GPA is a systemic autoimmune disease of unknown etiology. It is frequently associated with antineutrophilic cytoplasmic antibodies (ANCA) against serine proteinase 3 (PR3). Although any organ can be affected, only a few reports about urogenital GPA manifestation in organs, such as prostate, seminal vesicles, testis, bladder, and penis, have been reported [2-5]. Here we report a case of prostatic GPA granulation in a 65-year-old male who presented with an initial symptom of urinary dysuria.

2. Case Presentation

A 65-year-old male visited a community hospital complaining of urinary retardation, dysuria, and gross hematuria. The patient had history of hypertension, hyperuricemia, and hyperlipidemia. He had no family history of prostate cancer, and his prostate-specific antigen (PSA) value was 1.6 ng/mL (normal range: 0–4 ng/mL). A physical examination revealed low-grade fever. Administration of 4 mg of alpha blocker did not relieve his symptoms. Laboratory evaluations were as follows: hemoglobin (Hb), 9.6 g/mL, hematocrit (Ht), 28.9%, leukocytes, 8200 cells/mL, glucose, 175 mg/dL, creatinine, 0.65 mg/dL, and C-reactive protein (CRP), 17.96 mg/dL. Urinalysis noted 30–40 WBCs/hpf and 5–9 RBCs/hpf. Urine cytology is Class IIIa. Abdomen and pelvic computed tomography (CT) scan and magnetic resonance imaging (MRI) showed a lobular lesion with irregular edge and fluid collection in the left lobe of prostate (Figure 1).
Figure 1

Pelvic MRI ((a) axial and (b) sagittal) showed a lobular lesion, whose vicinity edge is irregular due to fluid collection in the left lobe of his prostate.

Chest CT scan in the presence of a dye showed bilateral, bizarre pulmonary nodules with cavitation and an enhancing mass of about 6.5 cm at its largest diameter (Figure 2).
Figure 2

Chest CT (mediastinal window) scan showed bilateral pulmonary nodules and a solid, enhancing mass with cavitation of 6.5 cm at its largest diameter.

This patient was admitted to a hospital for intensive examination. Thus, a transurethral resection of the prostate (TURP) as part of tissue sampling and a bronchoscopic examination were performed. Histologic examination of the prostate revealed accumulation and cellular infiltration of neutrophils and lymphocytes as well as histiocytosis and necrotizing tissues. These findings were consistent with those of GPA (Figure 3(a)). Histologic examination of lung lesions also showed accumulation and cellular infiltration of neutrophils and lymphocytes as well as histiocytosis with fibrinoid necrosis (Figure 3(b)).
Figure 3

Histopathological section ((a) prostate; (b) lung) showed fibrinoid necrosis, and the inflammatory infiltrate was predominantly composed of neutrophils, lymphocytes, and histiocytes (hematoxylin-eosin stain, original magnifications of (a) and (b) are 100x).

Cerebral MRI showed that T2WI high-iso signal occupied the area from right lateral maxillary to ethmoid sinus involving a fluid collection. An immunologic investigation showed positive c-ANCA with high anti-PR3 activity (296 U/mL). We diagnosed GPA as the systemic disease considering these results, and the patient was treated in the department of respiratory medicine.

3. Discussion

Involvement of the prostate in GPA is considered uncommon and has been reported in a few studies. Initially we suspected this case to be a prostate cancer with lung metastasis, bearing aggressive histology such as that of small cell carcinoma or undifferentiated carcinoma. Prostatitis is considered as one of the most common urogenital symptoms of GPA and was observed in 3 of the 8 patients in the previous study [5]. Prostatic involvement has also been reported in 2.3%–7.4% of the cases [6, 7]. However, when considering granulomatous prostatitis, Stillwell et al. reported that only 4 out of 200 cases appeared to have symptoms of GPA [8]. Histological examination of prostate and lung tumors revealed no malignancy in this case, and complicated maxillary sinusitis was detected from cerebral MRI for the purpose of searching for cerebral metastasis. Therefore, we suspected GPA as the systemic disease and checked for PR3-ANCA. ANCA is a serologic marker for various diseases such as systemic vasculitis [9, 10]. The cytoplasmic pattern with high anti-PR3 activity (PR3-ANCA) is relatively specific and sensitive for GPA [2]. When GPA is not previously recognized, positivity of PR3-ANCA in the context of isolated urogenital symptoms has a good diagnostic value. Results of PR3-ANCA testing should be interpreted cautiously when urogenital symptoms complicate the course of defined GPA in a treated patient. A reasonable conclusion cannot be drawn if the previous PR3-ANCA titer profile is not known. On the other hand, if serial titers are known to parallel or precede those of the clinical exacerbation of GPA in a given patient, they probably could help distinguish specific from nonspecific urogenital involvement. However, in the presence of urogenital symptoms, physicians should be aware that patients with tuberculosis could be falsely diagnosed as having GPA on the basis of ANCA test alone [11]. Indeed, although ANCA test results can be used by clinicians as adjunct evidence for the diagnosis of GPA in patients with limited urogenital symptoms, these results should be viewed in the context of the complete clinical picture of the patient and the prevalence of GPA in the clinical setting.

4. Conclusion

Symptomatic prostatic involvement is a rare feature of GPA but is probably underestimated because it is difficult to diagnose in some cases. If physicians come across patients that have urinary dysfunction symptoms and their radiograph shows a similar mass in their prostate and lungs, they should be aware of the possibility of GPA and consider performing examinations such as those for detecting PR3-ANCA.
  11 in total

1.  Prevalence of antineutrophil cytoplasmic autoantibodies in patients with tuberculosis.

Authors:  L F Flores-Suárez; J Cabiedes; A R Villa; F J van der Woude; J Alcocer-Varela
Journal:  Rheumatology (Oxford)       Date:  2003-02       Impact factor: 7.580

2.  Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis).

Authors:  E W WALTON
Journal:  Br Med J       Date:  1958-08-02

3.  Predicting mortality in systemic Wegener's granulomatosis: a survival analysis based on 93 patients.

Authors:  Dominique Bligny; Alfred Mahr; Philippe Le Toumelin; Luc Mouthon; Loïc Guillevin
Journal:  Arthritis Rheum       Date:  2004-02-15

4.  Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network.

Authors:  R J Falk; S Hogan; T S Carey; J C Jennette
Journal:  Ann Intern Med       Date:  1990-11-01       Impact factor: 25.391

5.  Standardized neurologic evaluations of 128 patients with Wegener granulomatosis.

Authors:  K de Groot; D K Schmidt; A C Arlt; W L Gross; E Reinhold-Keller
Journal:  Arch Neurol       Date:  2001-08

Review 6.  Antineutrophil cytoplasmic antibodies and associated diseases: a review of the clinical and laboratory features.

Authors:  J Savige; D Davies; R J Falk; J C Jennette; A Wiik
Journal:  Kidney Int       Date:  2000-03       Impact factor: 10.612

7.  The clinical spectrum of granulomatous prostatitis: a report of 200 cases.

Authors:  T J Stillwell; D E Engen; G M Farrow
Journal:  J Urol       Date:  1987-08       Impact factor: 7.450

8.  Urogenital manifestations of Wegener granulomatosis.

Authors:  D L Huong; T Papo; J C Piette; B Wechsler; O Bletry; F Richard; J C Valcke; P Godeau
Journal:  Medicine (Baltimore)       Date:  1995-05       Impact factor: 1.889

Review 9.  Antineutrophil cytoplasmic antibodies: a still-growing class of autoantibodies in inflammatory disorders.

Authors:  C G Kallenberg; A H Mulder; J W Tervaert
Journal:  Am J Med       Date:  1992-12       Impact factor: 4.965

10.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.

Authors:  J C Jennette; R J Falk; P A Bacon; N Basu; M C Cid; F Ferrario; L F Flores-Suarez; W L Gross; L Guillevin; E C Hagen; G S Hoffman; D R Jayne; C G M Kallenberg; P Lamprecht; C A Langford; R A Luqmani; A D Mahr; E L Matteson; P A Merkel; S Ozen; C D Pusey; N Rasmussen; A J Rees; D G I Scott; U Specks; J H Stone; K Takahashi; R A Watts
Journal:  Arthritis Rheum       Date:  2013-01
View more
  2 in total

Review 1.  Prostate involvement in granulomatosis with polyangiitis.

Authors:  Roman Yatsyshyn; Olena Zimba; Mykola Bahrii; Bohdana Doskaliuk; Vitalii Huryk
Journal:  Rheumatol Int       Date:  2019-05-09       Impact factor: 2.631

Review 2.  Identifying the deceiver: the non-neoplastic mimickers of genital system neoplasms.

Authors:  Omer Onder; Ali Devrim Karaosmanoglu; Jessica Kraeft; Aycan Uysal; Musturay Karcaaltincaba; Deniz Akata; Mustafa Nasuh Ozmen; Peter F Hahn
Journal:  Insights Imaging       Date:  2021-07-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.